Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II
Status: Enrolling
Updated:  12/31/1969
Oncare Hawaii, Incorporated - Pali Momi
mi
from
'Aiea, HI
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II
Status: Enrolling
Updated: 12/31/1969
Oncare Hawaii, Incorporated - Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer
A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer
A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
A Phase 1b Study of Bavituximab Plus Carboplatin and Pemetrexed in Chemotherapy-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Lineberger Comprehensive Cancer Center, UNC
mi
from
Chapel Hill, NC
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
A Phase 1b Study of Bavituximab Plus Carboplatin and Pemetrexed in Chemotherapy-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Lineberger Comprehensive Cancer Center, UNC
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
A Phase 1b Study of Bavituximab Plus Carboplatin and Pemetrexed in Chemotherapy-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
A Phase 1b Study of Bavituximab Plus Carboplatin and Pemetrexed in Chemotherapy-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-Austin
mi
from
Austin, TX
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-Austin
mi
from
Austin, TX
Click here to add this to my saved trials
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins
mi
from
Baltimore, MD
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated:  12/31/1969
Emory Healthcare
mi
from
Atlanta, GA
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated: 12/31/1969
Emory Healthcare
mi
from
Atlanta, GA
Click here to add this to my saved trials
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated:  12/31/1969
Washington University Medical Center St. Louis
mi
from
Saint Louis, MO
Effectiveness of Open and Robotic Prostatectomy
Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study
Status: Enrolling
Updated: 12/31/1969
Washington University Medical Center St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer
Armodafinil for Persistent Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer: a Randomized Phase II Study
Status: Enrolling
Updated:  12/31/1969
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer
Armodafinil for Persistent Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer: a Randomized Phase II Study
Status: Enrolling
Updated: 12/31/1969
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer
Armodafinil for Persistent Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer: a Randomized Phase II Study
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer
Armodafinil for Persistent Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer: a Randomized Phase II Study
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
Sirolimus in Combination With Metronomic Therapy in Children With Recurrent and Refractory Solid Tumors: A Phase I Study
Status: Enrolling
Updated:  12/31/1969
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
Sirolimus in Combination With Metronomic Therapy in Children With Recurrent and Refractory Solid Tumors: A Phase I Study
Status: Enrolling
Updated: 12/31/1969
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
TPI 287 in Breast Cancer Metastatic to the Brain
A Phase 2 Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
TPI 287 in Breast Cancer Metastatic to the Brain
A Phase 2 Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
UCLA Hematology-Oncology
mi
from
Santa Monica, CA
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
UCLA Hematology-Oncology
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
Camino Medical Group - Treatment Center
mi
from
Mountain View, CA
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
Camino Medical Group - Treatment Center
mi
from
Mountain View, CA
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
Palo Alto Medical Foundation
mi
from
Palo Alto, CA
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
Palo Alto Medical Foundation
mi
from
Palo Alto, CA
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Christiana Care Health Services
mi
from
Newark, DE
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
Kuakini Medical Center
mi
from
Honolulu, HI
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
Kuakini Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
OnCare Hawaii, Incorporated - Lusitana
mi
from
Honolulu, HI
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
OnCare Hawaii, Incorporated - Lusitana
mi
from
Honolulu, HI
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
Queen's Cancer Institute at Queen's Medical Center
mi
from
Honolulu, HI
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
Queen's Cancer Institute at Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
Castle Medical Center
mi
from
Kailua, HI
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
Castle Medical Center
mi
from
Kailua, HI
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Carle Cancer Center
mi
from
Urbana, IL
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
McFarland Clinic, PC
mi
from
Ames, IA
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
McFarland Clinic, PC
mi
from
Ames, IA
Click here to add this to my saved trials